Hear from two of our global leaders, Dominique Legros and Jon Gingrich, how Echosens is poised for exceptional growth as we focus on the assessment of chronic liver disease against the looming worldwide epidemic of NAFLD.
Echosens recently recruited Dominique Legros to lead the company as global CEO. Medgadget caught up with him to learn more about the company and his goals for its future.
In this white paper, we explore the growing body of data that show how nonalcoholic fatty liver disease (NAFLD) is becoming recognized as a significant burden to patients, providers, and the overall healthcare system. One study concluded that the costs associated with the care for NAFLD were significantly higher than matched controls with similar metabolic profiles, even before the introduction of pharmacological treatments